Final results of XRP6976D: Preoperative TAC (docetaxel, doxorubicin, cyclophsophamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer

628 Background: In Australia, there is no consistent management approach for locally advanced breast cancer (LABC). Our aim was to assess the feasibility of a standardized multidisciplinary protocol for the management of LABC. In addition, MRI and PET accuracy in predicting extent of residual disease following 6 cycles of TAC was evaluated. Methods: Patients with LABC, (T3/4, N2/3, M0); ECOG 0/1, received preoperative chemotherapy (docetaxel 75mg/m2, doxorubicin 50mg/m2, cyclophosphamide 500mg/m2 (TAC) q21 days for 6 cycles, unless progression or intolerable toxicity). Breast and regional nodes were monitored clinically and by ultrasound. MRI and PET performed at baseline and after cycle 6. Mastectomy or local excision with axillary clearance was done and post-surgery radiotherapy given according to the predetermined protocol. Adjuvant trastuzumab and endocrine therapy given as appropriate. Results: 50 patients were included from three institutions in Perth, Western Australia, April 2005 to October 2006. ...